# High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors

> **NCT00571584** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 24 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A With Inhibitors
- Haemophilia B With Inhibitors

## Interventions

- **DRUG:** activated recombinant human factor VII

## Key facts

- **NCT ID:** NCT00571584
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2004-03
- **Final completion:** 2004-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00571584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00571584, "High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00571584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*